PMID: 16649535May 3, 2006Paper

New tacrine-hydrazinonicotinamide hybrids as acetylcholinesterase inhibitors of potential interest for the early diagnostics of Alzheimer's disease

Die Pharmazie
P SzymańskiE Mikiciuk-Olasik

Abstract

The syntheses and the preliminary results of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibition by an affinity series of tacrine-hydrazinonicotinamide hybrids are described. These molecules were prepared by condensation of tacrine analogues with the hydrazine nicotinate moiety (HYNIC). Derivatives 6a and 6b showed lower activity than the model tacrine, while compounds 6c and 6d showed the strongest affinity to AChE. All the tested compounds exhibited lower affinity for BChE than tacrine. Alzheimer disease (AD) is characterised by a deficit of acetylcholinesterase, and these new compounds, as ligands for 99mTc complexes, are potential radiopharmaceuticals for an early diagnosis of Alzheimer's disease.

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.